Sartorius Stedim stock faces EUR 260 target as Q3 nears

Published on 09/29/2026 at 17:32 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Sartorius Stedim stock generated EUR 1,527.0 million in H1 2026 revenue and EUR 463.7 million EBITDA. JPMorgan expects a slight Q3 beat before the October report.

Fotorealistische Aufnahme einer sterilen Bioprozessanlage mit Einwegbeuteln und Bioreaktoren — Sartorius Stedim Biotech produziert sterile Einwegbeutel und Bioreaktoren für Biopharma-Hersteller weltweit, ISIN FR0013154002, Illustration mit AI erstellt.

Sartorius Stedim Biotech (ISIN FR0013154002) generated EUR 1,527.0 million in first-half 2026 revenue and EUR 463.7 million in EBITDA. The company enters the next reporting milestone with annual guidance of EUR 3,153.8 million in revenue and EUR 989.2 million in EBITDA, while JPMorgan expects a slight third-quarter beat.

JPMorgan keeps EUR 260 target

According to wallstreetONLINE on September 28, 2026, JPMorgan maintained its Overweight rating and EUR 260.00 price target for Sartorius Stedim. Analyst Richard Vosser expects Sartorius and its listed subsidiary to slightly exceed third-quarter expectations, with reports scheduled for October 22, 2026.

The target is EUR 42.40 above the EUR 217.60 Euronext Paris quote, equivalent to 19.49 percent. That gap gives the analyst view a concrete valuation signal, but it also leaves the stock dependent on evidence that biopharmaceutical equipment demand is recovering.

Guidance sets the earnings test

Ideal Investisseur reported on September 29, 2026, that Sartorius Stedim had confirmed its full-year targets after publishing first-half results on July 22, 2026. The reported first-half figures included EUR 181.1 million in net income and an EBITDA margin of 31.4 percent.

The guidance places the next quarter under a clear test. Delivering the expected improvement would support the annual revenue and EBITDA targets, while another weak demand signal would challenge the valuation already reflected in the analyst target.

Stock remains near yearly high

Sartorius Stedim was last at EUR 217.60 on Euronext Paris on September 29, 2026, at 5:16 p.m. CEST. The quote stood 2.86 percent below the EUR 224.00 52-week high and the company had a market capitalization of EUR 21.2 billion on the same date.